At 11 million cases annually, urinary tract infections (UTIs) are the most common outpatient infections in the U.S., according to the U.S. Department of Health and Human Services. At least half of all women will have a UTI during their lifetimes, and many of the infections — which have increasingly become resistant to a wide array of antibiotics — recur. Now, researchers report early progress toward developing a new class of antibiotics that would fight these infections by starving the causative bacteria of iron.

“You can’t stop bacteria from evolving and developing resistance to antibiotics,” says Mary Rose Ronquillo, an undergraduate student who works in the lab of Scott C. Eagon, Ph.D. “The aim of our research is to develop a drug that acts in a different way from current drugs — by depriving the bacteria of iron, a key nutrient essential to their survival.”

Currently, most drugs that treat UTIs caused by uropathogenic E. coli (UPEC) either disrupt synthesis of the bacterial cell wall or interfere with bacterial DNA replication. Since the urinary tract is an iron-deficient environment, UPEC have evolved several ways to obtain iron, such as by producing molecules called siderophores that sop up iron bound to host proteins.

The researchers, who are at California Polytechnic State University, have collaborated on this project with other scientists at the University of Michigan School of Medicine. The collaborators previously showed that the iron acquisition process can be a target for small molecules for possible UTI treatment. In that study, they screened nearly 150,000 compounds and identified 16 that stop these bacteria from growing under iron-limiting conditions. Of these 16, two compounds were linked to disruption of the bacterial TonB system, which consists of three transmembrane proteins that help UPEC take up iron. Eagon’s group is focusing on these two compounds for further study.

“We selected one of these compounds as a scaffold to modify into potential small molecule inhibitors of the TonB system,” M. Cole Detels, an undergraduate student in Eagon’s lab, explains. The molecule is called 2-{[(3-chloro-4-methoxyphenyl)amino]methyl}quinolin-8-ol, or more simply, the “hydroxyquinoline scaffold.”

After they made the scaffold molecule, Detels and Ronquillo prepared five variations, and another three are now in the purification stage. “While the synthesis of the potential drugs is relatively straightforward, purifying them from the soup of other chemicals used in their preparation has been challenging,” Detels says.

The team says that the goal is to prepare a library of inhibitors in which the hydroxyquinoline scaffold is modified with various functional groups. “With this library in hand, we will work with our collaborators to screen them against UPEC and human cell lines to look for broad toxicity,” Eagon says. “After that, the compounds will be tested in animal models to see if they kill the bacteria in vivo.” Once Eagon’s team finishes preparing the complete hydroxyquinoline library, they plan to make variations of the second scaffold molecule.

Because they target iron uptake, this new class of drugs is expected to have no effect on beneficial E. coli strains in other regions of the body. Iron is plentiful in the body in non-urinary tract locations, so hindering iron uptake shouldn’t cause a problem for these bacteria. Most current antibiotics, however, wipe out all strains, including beneficial gut flora. And because there is no TonB homolog found in humans, the possibility of toxic side effects would also be reduced compared to other antibiotics.

Source: acs.org